HeartFlow wins Japanese reimbursement for FFRct analysis

HeartFlow said yesterday that it won reimbursement coverage from the Japanese Ministry of Health, Labor and Welfare for its HeartFlow FFRct fractional flow reserve analysis. The Redwood City, Calif.-based company said that it has already received approval from the Japanese Pharmaceuticals and Medical Devices Agency, and that reimbursement will go into effect beginning on December 1. “When a patient presents with symptoms suggesting CAD, we want to be able to quickly and effectively diagnose patients while reducing the need for unnecessary tests or invasive procedures. In clinical studies, we were able to see firsthand how the HeartFlow Analysis can help to improve patient management and avoid invasive procedures in some patients. The reimbursement approval will enable more physicians and patients to obtain benefits from this ground-breaking technology,” Dr. Takashi Akasaka of Wakayama Medical University said in a prepared statement. The HeartFlow analysis is a non-invasive, personalized cardiac test that applies artificial intelligence to image data taken from standard coronary computed tomography scans to produce a digital 3D model of a patient’s arteries. The system then applies algorithms to assess the impact of blockages on blood flow to the heart, the company said. “Adding the HeartFlow Analysis to the anatomical information provided by a coronary CT angiogram enables us to better detect and treat CAD. With the broader availability of the HeartFl...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Cardiovascular Featured Imaging Software / IT HeartFlow Source Type: news